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Abstract
Objectives To assess the effects of rivastigmine on the
core domains of Alzheimer’s disease.
Design Prospective, randomised, multicentre, double
blind, placebo controlled, parallel group trial. Patients
received either placebo, 1›4 mg/day (lower dose)
rivastigmine, or 6›12 mg/day (higher dose)
rivastigmine. Doses were increased in one of two fixed
dose ranges (1›4 mg/day or 6›12 mg/day) over the
first 12 weeks with a subsequent assessment period of
14 weeks.
Setting 45 centres in Europe and North America.
Participants 725 patients with mild to moderately
severe probable Alzheimer’s disease diagnosed
according to the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, and the criteria of the
National Institute of Neurological and
Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders
Association.
Outcome measures Cognitive subscale of the
Alzheimer’s disease assessment scale, rating on the
clinician interview based impression of change
incorporating caregiver information scale, and the
progressive deterioration scale.
Results At the end of the study cognitive function had
deteriorated among those in the placebo group.
Scores on the Alzheimer’s disease assessment scale
improved in patients in the higher dose group when
compared with patients taking placebo (P < 0.05).
Significantly more patients in the higher dose group
had improved by 4 points or more than had improved
in the placebo group (24% (57/242) v 16% (39/238)).
Global function as rated by the clinician interview
scale had significantly improved among those in the
higher dose group compared with those taking
placebo (P < 0.001), and significantly more patients in
the higher dose group showed improvement than did
in the placebo group (37% (80/219) v 20% (46/230)).
Mean scores on the progressive deterioration scale
improved from baseline in patients in the higher dose
group but fell in the placebo group. Adverse events
were predominantly gastrointestinal, of mild to
moderate severity, transient, and occurred mainly
during escalation of the dose. 23% (55/242) of those
in the higher dose group, 7% (18/242) of those in the
lower dose group, and 7% (16/239) of those in the
placebo group discontinued treatment because of
adverse events.
Conclusions Rivastigmine is well tolerated and
effective. It improves cognition, participation in
activities of daily living, and global evaluation ratings
in patients with mild to moderately severe Alzheimer’s
disease. This is the first treatment to show compelling
evidence of efficacy in a predominantly European
population.
Introduction
One of the most successful treatments for Alzheimer’s
disease has been the use of acetylcholinesterase
inhibitors to enhance surviving cholinergic neurotrans›
mission by inhibiting the breakdown of released
acetylcholine. The first of these drugs approved for
treating Alzheimer’s disease, tacrine, is effective but can
cause an increase in liver enzyme concentrations; in
some countries, such as in the United Kingdom, this has
prevented it from being licensed.1–3 More recently, a sec›
ond acetylcholinesterase inhibitor, donepezil (a piperid›
ine derivative) has become available.4 5 Clinical trials
have reported benefits on cognition and global
evaluations.4 5 Rivastigmine is a novel, “pseudo›
irreversible,” brain selective inhibitor of acetylcholineste›
rases, the metabolism of which is almost totally
independent of the hepatic cytochrome P450 system.6–8
The aim of this study was to evaluate the safety and
efficacy of two doses of rivastigmine (1›4 mg/day and
6›12 mg/day) compared with a placebo over 26 weeks
in patients with probable Alzheimer’s disease. The
study was carried out predominantly in European
centres using a design similar to that employed in a
parallel study in North America9 as part of a global
evaluation programme (Alzheimer’s disease treatment
with ENA›713)10 This programme is the largest
programme of clinical trials conducted to date for
treatment for dementia; it consists of four trials with
over 3300 patients at 111 centres in 10 countries.
Participants and methods
Patients
To be enrolled in the study patients had to be 50›85
years of age and not able to bear children (older or
younger patients could enter the study with the
approval of the medical expert (MG or AC›S). All
patients met criteria for Alzheimer’s type dementia as
described in the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition11 and criteria for prob›
able Alzheimer’s disease according to criteria of the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association.12 Participants also had
to have scores of 10›26 on the mini›mental state exam›
ination.13 Most patients were recruited from the
community either through their general practitioners
or directly, and each patient had a responsible
caregiver and, along with their caregiver, provided
website
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written informed consent. Patients with concomitant
diseases such as hypertension, non›insulin dependent
diabetes, and arthritis were included. Only those with
severe and unstable cardiac disease, severe obstructive
pulmonary disease, or other life threatening conditions
(such as rapidly progressing malignancies) were
excluded. Patients taking drugs for coexistent diseases
were included except for those taking anticholinergic
drugs, health food supplements containing acetylcho›
line precursors, putative memory enhancers, insulin,
and psychotropic drugs (the use of small doses of short
acting benzodiazepines, chloral hydrate, or haloperidol
was allowed). The trial procedures were in accord with
the ethical standards of the institutional committees on
human experimentation and with the Helsinki
Declaration. The study was overseen by an independ›
ent international safety monitoring board. (A list of
members of the board appears on the BMJ’s website.)
Design
The 26 week study, conducted at 45 centres in Europe
(in Austria, France, Germany, and Switzerland) and in
North America, utilised a randomised, double blind,
placebo controlled, parallel group design. Patients
were randomly allocated either to placebo or 1›4 mg/
day rivastigmine (lower dose) or 6›12 mg/day (higher
dose) according to a computer generated randomisa›
tion code at Novartis Pharma (Basle, Switzerland). To
maintain blinding capsules containing rivastigmine
and placebo were identical and the number taken was
the same at each dose in all groups. Dosages were
increased weekly in steps of up to 1.5 mg/day during
weeks 1›12 (dose escalation phase) and had to be
within the target range by week 7. Decreases in doses
were not permitted during this phase. However, if
adverse events occurred a dose could be omitted,
maintained without increase for two consecutive
weeks, or antiemetic drugs could be given. During
weeks 13›26 (maintenance) doses could be increased
or decreased within the assigned range with the aim of
administering the highest dose that was well tolerated.
Efficacy measures fulfilled the US Food and Drug
Administration’s dual efficacy requirements for clinical
trials for Alzheimer’s disease—that is, improvement on
a performance based cognitive instrument and
demonstration that the improvement was clinically
meaningful.14 Efficacy was assessed on the cognitive
subscale of the Alzheimer’s disease assessment scale,15
the clinician interview based impression of change
incorporating caregiver information,16 and the pro›
gressive deterioration scale.17 Efficacy evaluations were
performed at baseline and weeks 12, 18, and 26 or at
early withdrawal from the trial. Table 1 summarises the
instruments used, symptoms and domains measured,
the source of information, the range of scores, and
their interpretation.
The mini›mental state examination13 and the global
deterioration scale18 were used as staging measures at
baseline and week 26.
Safety evaluations included physical examinations,
electrocardiography, monitoring vital signs, and labo›
ratory testing. Adverse events were coded using the
Sandoz medical technology thesaurus, which is based
on a WHO document. Three central laboratories (in
Europe, the United States, and Canada) performed all
clinical laboratory evaluations, and one cardiologist at
a central analysis centre read all electrocardiograms.
Statistical methods
The study sample population of about 200 in each
group was planned to enable achievement of 90%
power with á = 0.05 for detecting at least a 3.0 point
improvement on the Alzheimer’s disease assessment
scale and an increase from 15›30% among patients
scoring < 4 on the clinician impression of change scale.
Patients were classed for efficacy analyses as: classi›
cal intention to treat, traditional last observation
carried forward (randomised patients with at least one
evaluation while being treated), and observed cases
(randomised patients with an evaluation made while
on study drug at designated assessment times).
Comparisons with placebo were two tailed with the
critical level set at P < 0.05. Analyses of efficacy utilised
the clinician impression of change scale with analysis
of variance and two tailed pairwise Student’s t tests
using the pooled error term from the analysis of
variance (sas type III analysis); the Alzheimer’s assess›
ment scale and the progressive deterioration scale with
analysis of covariance and variance and two tailed pair›
wise Student’s t tests using the pooled error term from
the analysis of covariance and variance (sas type III
analysis); the Alzheimer’s assessment scale, the
clinician impression of change scale and the progres›
sive deterioration scale (categorical analyses) with
Mantel›Haenszel blocking for centre. Safety analyses
used an analysis of variance for vital signs, laboratory
data, and electrocardiograms, and Fisher’s exact test for
the occurrence of abnormalities on physical examina›
Table 1 Instruments used to evaluate the efficacy of rivastigmine in treating Alzheimer’s disease
Instrument Symptoms or domains assessed Source of information Range of scale and interpretation
Alzheimer’s disease assessment
scale (cognitive subscale)
Cognition (memory, language, orientation,
praxis)
Patient 0›70 points
0=no errors (rarely achieved, even in general
population)
70=severe impairment
Clinician interview based impression
of change scale (incorporating
caregiver information)
Global assessment of behaviour, general
psychopathology, cognition, and activities
of daily living
Patient and caregiver during
interview with clinician*
1›7 points
1, 2, 3=marked, moderate, or minimal
improvement
4=no change
5, 6, 7=minimal, moderate, or marked
deterioration
Progressive deterioration scale Activities of daily living (dressing and
eating independently, social interaction,
participation in housework and hobbies,
awareness of time, handling of financial
matters)
Caregiver 29 items
Scores range from 0 to 100
*Clinicians had no access to data on efficacy or safety.
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tions, electrocardiograms, vital signs, laboratory tests,
and adverse events.
Results
The randomisation of patients and their progress
through the study is summarised in figure 1. A total of
831 patients were recruited; 106 of these were
excluded. Altogether 243 patients were randomly
allocated to higher dose treatment, 243 to lower dose,
and 239 to placebo. Demographic variables and
disease characteristics at baseline were comparable
across groups but there were more females (59%
(428/725)) than males (41% (297/725)). Mean age
was 72 years (range 45›95 years), and most patients
(97% (703/725)) were white. The mean duration of
dementia was 39 months; 41% (298/725) of patients
had mild disease, 57% (411/725) moderate, and 2%
(16/725) had severe disease.18 The mean scores at base›
line on the Alzheimer’s disease assessment scale and the
progressive deterioration scale for the three groups are
shown in table 2. The mean score on the mini›mental
state examination was 19.9 (range 10›29).
About 80% of patients (579/725) reported prior or
current medical conditions, or both. These were most
commonly cardiovascular. About 81% (590/725) were
taking concomitant drug treatment at baseline. The
mean number of medical conditions per patient was
2.5 and the mean number of concomitant drugs being
taken per patient was 4.0. The most common
drugs—that is, taken by > 10% in each group—
included anti›infectives and drugs for cardiovascular,
gastrointestinal, respiratory, musculoskeletal, blood,
and nervous system disorders.
By the end of the study the mean dose of
rivastigmine was 10.4 (SD 2.13) mg/day in the higher
dose group and 3.7 (SD 0.59) mg/day in the lower dose
group. Of the patients who were taking rivastigmine
until the end of the study, 64% (107/166) in the higher
dose group and 90% (190/210) in the lower dose
group reached the maximum prescribed dose.
Table 3 summarises the effects of rivastigmine on
all measures of efficacy.
Cognitive subscale of the Alzheimer’s disease assessment scale
Cognitive function worsened progressively in patients
taking placebo. The mean deterioration in the cognitive
subscale was 1.41 points over 26 weeks among observed
cases (fig 2). The mean score on the subscale improved
among patients in the higher dose group (mean
improvement 1.17 points). Differences between the two
groups in the mean change from baseline scores were
statistically significant at weeks 12, 18, and 26 for all
three analyses. Of the patients completing the study 55%
(86/157) of those in the higher dose group improved
from baseline measurements compared with 45%
(93/205) of those treated with placebo (analysis of
observed cases). The proportion of patients with a clini›
cally meaningful improvement in their scores (defined
as a change of four points or more from baseline) at the
end of the study was significantly greater among patients
receiving higher dose rivastigmine than among those
taking placebo (24% (57/242) higher dose group v 16%
(39/238) placebo in intention to treat analysis; 27% (53/
199) higher dose group v 18% (40/225) last observation
carried forward; and 29% (45/157) higher dose group v
19% (38/205) observed cases analysis (P < 0.05)).
Clinician interview based impression of change
At week 26 patients treated with placebo had
deteriorated (mean rating 4.34) (table 4). Patients in the
higher dose rivastigmine group had improved (mean
rating 3.93). The difference between the two groups at
week 26 was statistically significant for all three efficacy
analyses. At week 26 significantly more patients in both
rivastigmine groups had ratings of marked, moderate,
or minimal improvement on this scale when compared
with those taking placebo (20% (46/230) placebo
group v 30% (69/233) lower dose group (P < 0.05) and
37% (80/219) higher dose group (P < 0.001) in the
intention to treat analysis; 22% (49/226) placebo
group v 32% (71/224) lower dose group (P < 0.01) and
40% (78/193) higher dose group (P < 0.001) in the last
observation carried forward; 22% (44/197) placebo
group v 31% (62/198) lower dose group (P < 0.05) and
41% (63/155) higher dose group (P < 0.001) in the
observed cases analysis).
Progressive deterioration scale
At week 26 the difference in mean change from base›
line in scores on the progressive deterioration scale
between patients receiving placebo and those receiving
higher dose rivastigmine was statistically significant in
the analysis of the last observation carried forward
(P < 0.05) (fig 3). Of the 581 patients completing the
Patients recruited (n=831)
Patients excluded (n=106)
Lower dose rivastigmine
(n=243)
Placebo
(n=239)
Higher dose rivastigmine
(n=243)
Completed trial (n=209)Completed trial (n=208) Completed trial (n=164)
Follow up
12 weeks (n=226)
18 weeks (n=219)
26 weeks (n=210)
Follow up
12 weeks (n=226)
18 weeks (n=218)
26 weeks (n=208)
Follow up
12 weeks (n=191)
18 weeks (n=179)
26 weeks (n=166)
Treatment discontinued (n=31)
Reason for withdrawal
Treatment discontinued (n=34)
Reason for withdrawal
Treatment discontinued (n=79)
Reason for withdrawal
Withdrawal of consent
Failure to return
Treatment failure
Adverse event
Death
Non-compliance
Other
6
2
2
16
0
1
4
Withdrawal of consent
Failure to return
Treatment failure
Adverse event
Death
Non-compliance
Other
5
3
1
18
0
2
5
Withdrawal of consent
Failure to return
Treatment failure
Adverse event
Death
Non-compliance
Other
11
2
2
55
1
3
5
Randomisation (n=725)
Fig 1 Outcome of allocation to treatment and reasons for withdrawal from the study
Table 2 Mean (range) baseline scores analysed on an intention to treat basis
Instrument
Rivastigmine groups
Placebo (n=243)Higher dose (n=243) Lower dose (n=243)
Alzheimer’s disease assessment
scale (cognitive subscale)
23.57 (5.7›58.0) 23.87 (4›60.7) 23.29 (3.3›57.8)
Progressive deterioration scale 55.22 (9.5›94.6) 53.8 (9.9›94) 54.1 (7.1›93.5)
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study, a significant difference in those showing any
improvement in these scores was observed for those
taking higher dose rivastigmine compared with those
taking placebo (49% (98/198) v 39% (88/223) respec›
tively; P = 0.04 in analysis of the last observation
carried forward). Significantly more patients in the
higher dose group improved by at least 10% than did
in the placebo group both in the intention to treat
analysis (29% (70/241) v 19% (45/237), P < 0.01) and
the analysis of the last observation carried forward
(33% (66/198) v 20% (45/223), P < 0.01).
Table 3 Mean (95% confidence interval) change from baseline on measures of efficacy of rivastigmine at week 26
Instrument
Treatment group and analysis
Higher dose rivastigmine Lower dose rivastigmine Placebo
Intention to
treat analysis
Last
observation
carried
forward
analysis
Observed
cases analysis
Intention to
treat analysis
Last
observation
carried forward
analysis
Observed cases
analysis
Intention to
treat analysis
Last
observation
carried forward
analysis
Observed cases
analysis
Alzheimer’s disease
assessment scale
(cognitive subscale)
0.26
(−0.66 to 1.06)
0.83
(−0.19 to 1.79)
1.17
(−0.07 to 2.27)
−1.37
(−2.27 to −0.53)
−1.24
(−2.23 to −0.37)
−1.24
(−2.31 to −0.29)
−1.34
(−2.19 to −0.41)
−1.45
(−2.33 to −0.47)
−1.41
(−2.43 to −0.37)
P value v placebo <0.1 <0.001 <0.001 >0.05 >0.05 >0.05
No (%) patients with
>4 point
improvement
57/242 (24) 53/199 (27) 45/157 (29) 36/242 (15) 36/226 (16) 34/202 (17) 39/238 (16) 40/225 (18) 38/205 (19)
P value v placebo <0.1 <0.05 <0.05 >0.05 >0.05 >0.05
Clinician interview
based impression
of change scale
3.91
(3.71 to 4.09)
3.88
(3.69 to 4.11)
3.93
(3.67 to 4.13)
4.24
(4.02 to 4.38)
4.17
(4.0 to 4.4)
4.20
(3.99 to 4.41)
4.38
(4.22 to 4.58)
4.32
(4.1 to 4.5)
4.34
(4.09 to 4.51)
P value v placebo <0.001 <0.001 <0.05 >0.05 >0.05 >0.05
No (%) patients with
improvement
(scores 1, 2 or 3)
80/219 (37) 78/193 (40) 63/155 (41) 69/233 (30) 71/224 (32) 62/198 (31) 46/230 (20) 44/220 (22) 44/197 (22)
P value v placebo <0.001 <0.001 <0.001 <0.05 <0.01 <0.05
Progressive
deterioration scale
0.05
(−1.57 to 1.77)
0.5
(−1.32 to 2.52)
1.3
(−0.95 to 3.55)
−3.37
(−4.99 to −1.61)
−3.31
(−5.1 to −1.5)
−2.9
(−4.83 to −0.97)
−2.18
(−3.91 to −0.49)
−2.23
(−4.02 to −0.38)
−1.9
(−3.84 to 0.04)
P value v placebo <0.1 <0.05 <0.04 >0.05 >0.05
No (%) patients with
>10% improvement
70/241 (29) 66/198 (33) NP 45/241 (19) 45/225 (20) NP 45/237 (19) 45/223 (20) NP
P value v placebo <0.01 <0.01 >0.05 >0.05
Global deterioration
scale
−0.06
(−0.2 to 0.0)
−0.03
(−0.13 to 0.13)
NP −0.22
(−0.3 to −0.1)
−0.2
(−0.31 to −0.09)
NP −0.26
(−0.4 to −0.2)
−0.24
(−0.31 to −0.09)
NP
P value v placebo <0.05 <0.05
Mini›mental state
examination
0.21
(−0.24 to 0.64)
0.34
(−0.25 to 0.85)
NP −0.62
(−1.05 to −0.15)
−0.60
(−1.08 to −0.12)
NP −0.47
(−0.96 to −0.04)
−0.54
(−0.99 to −0.01)
NP
P value v placebo <0.05 <0.05
NP=analysis not planned.
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18 26
-2
0
1
Deterioration
Improvement
2
-1 Placebo
Lower dose rivastigmine (1-4 mg/day)
Higher dose rivastigmine (6-12 mg/day)
* P<0.05 compared with placebo
Fig 2 Mean change in baseline scores on cognitive subscale of
Alzheimer’s disease assessment scale, observed cases analysis.
P<0.05 compared with placebo (two tailed pairwise Student’s t tests
using pooled error term from analysis of covariance and analysis of
variance
Table 4 Mean scores (95% confidence intervals) on the clinician interview based
impression of change scale (incorporating caregiver information) at weeks 12, 18, and
26 among the observed cases population
Week Placebo
Rivastigmine groups
Lower dose Higher dose
12 3.96 (3.83 to 4.17) 4.01 (3.83 to 4.17) 3.88 (3.72 to 4.08)
18 4.09 (3.92 to 4.28) 4.06 (3.92 to 4.28) 3.85 (3.7 to 4.1)
26 4.34 (4.09 to 4.51) 4.20 (3.99 to 4.41) 3.93* (3.67 to 4.13)
*P<0.05 compared with placebo (pairwise Student’s t tests using pooled error terms from analysis of
variance).
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*
18 26
-3.5
-1.5
-0.5
Deterioration
Improvement
0.5
-2.5
-2
-1
0
-3
Placebo
Lower dose rivastigmine (1-4 mg/day)
Higher dose rivastigmine (6-12 mg/day)
* P<0.05 compared with placebo
Fig 3 Mean change in baseline scores on the progressive
deterioration scale, analysis of last observation carried forward.
P<0.05 compared with placebo (two tailed pairwise Student’s t tests
using pooled error term from analysis of covariance and analysis of
variance
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Global deterioration scale and mini›mental state
examination
At week 26 patients who had received rivastigmine
6›12 mg/day had a significantly better response than
those in the placebo group in the mean change from
baseline scores on the mini›mental state examination
and the global deterioration scale. Patients receiving
placebo deteriorated by 0.47 points from baseline on
the mini›mental state and those receiving rivastigmine
6›12 mg/day improved by 0.21 points over baseline
using the intention to treat analysis. Significantly less
deterioration occurred on the global deterioration
scale among patients taking 6›12 mg/day rivastigmine
compared with those taking placebo.
Safety
Of the 725 patients initially randomly allocated 581
(80%) completed treatment. The proportion who
discontinued treatment for any reason was significantly
higher in the higher dose group than in the lower dose
or placebo groups (33% (79/243) v 14% (34/243) and
13% (31/239), respectively) as was the proportion who
discontinued because of adverse events (23% (55/242)
v 7% (18/242) and 7% (16/239), respectively). Most of
the discontinuations related to adverse events occurred
during dose escalation (69% (38/55) in the higher dose
group).
The safety of the drug could be evaluated in 242
patients in each of the rivastigmine treatment groups
and in 239 patients in the placebo group. A summary
of the adverse events that occurred at least 5% more
often with rivastigmine than with placebo or that
occurred with an incidence significantly different from
placebo is given in table 5. Overall, significantly more
patients reported at least one treatment related adverse
event in the higher dose group (91% (220/242)) than
in the lower dose (71% (172/242)) or placebo (72%
(172/239)) groups.
Adverse events related to treatment were generally
not severe and occurred most frequently during the
dose escalation phase. The adverse events most
commonly reported with rivastigmine were choliner›
gic: nausea, vomiting, diarrhoea, abdominal pain, and
anorexia. Dizziness, headache, fatigue, and malaise also
occurred more frequently with higher doses of
rivastigmine than with placebo. Apart from the
incidence of nausea, there was no significant difference
in the incidence of adverse events between the lower
dose group and the group treated with placebo. The
frequency of serious adverse events was similar in all
groups (about 18%).
There were no obvious overall trends or clinically
relevant differences between treatment groups in vital
signs (mean systolic and diastolic blood pressure, abnor›
malities of blood pressure, heart rate, and body
temperature), physical examination, haematological or
biochemical analyses (including hepatic enzyme levels),
electrocardiographic measurement, or urine analysis.
Mean body weight increased in the placebo group
(mean change + 0.72 kg at week 26) but decreased in
the rivastigmine groups (mean change − 1.39 kg in the
higher dose group and − 0.13 kg in the lower dose). The
difference in the mean change in body weight between
the placebo group and the higher dose rivastigmine
group was statistically significant (Fisher’s exact test
P < 0.05). In the higher dose group 24% of patients (55/
234) lost > 7% of body weight compared with 9% of
patients (21/236) in the lower dose group and 7% (16/
236) in the placebo group.
Discussion
This study provides evidence of the efficacy of rivastig›
mine in alleviating the core cognitive and functional
symptoms of patients with mild to moderately severe
Alzheimer’s disease over 6 months. Rivastigmine was
effective on each of the measures of efficacy applied,
reflecting improvements in cognition as rated by
psychometricians, global functioning as rated by an
independent clinician, and activities of daily living as
rated by a caregiver. The effects of rivastigmine were
dose dependent.
Cognitive and global assessments
Compared with the 55% of patients taking placebo
who experienced a decline in cognitive function
during the study, patients treated with 6›12 mg/day of
rivastigmine improved. Cognitive function in patients
with Alzheimer’s disease who are not treated can be
expected to deteriorate. Estimates of the rate of decline
vary from as little as 1.28 points on the cognitive
subscale of the Alzheimer’s disease assessment scale over
24 weeks19 to as much as 9 points over 1 year.20 Other
estimates of the average rate of decline are 5.2 points on
the cognitive subscale over 1 year,15 7 points over 1
year,21 and about 5 points over 5 to 9 months.22 The sta›
bilisation of cognitive decline seen over 6 months in this
study in 55% of patients taking 6›12 mg/day of rivastig›
mine is therefore relevant to clinical practice.
Mean ratings on the clinician interview based
impression of change were consistently and signifi›
cantly superior for the group taking 6›12 mg/day of
rivastigmine when compared with placebo, and signifi›
cantly more patients treated with rivastigmine (in both
dosage groups) experienced global improvement than
did those taking the placebo.
Effects on activities of daily living
Perhaps the most relevant effects of rivastigmine
observed in this study are those on activities of daily
living. Poor performance of these activities is
correlated with admission to long term care facili›
ties.23 24 Poor performance is also recognised as an
important determining factor of the use of support
services by caregivers.25 The improvements in these
activities shown here are the first to be reported in a
prospective analysis of a global clinical trial. More than
Table 5 Number (percentage) of adverse effects occurring at least 5% more often in
patients taking rivastigmine than in patients taking placebo or occurring with an
incidence significantly different from placebo
Adverse effect
Rivastigmine groups
Placebo (n=239)Higher dose* (n=242) Lower dose (n=242)
Nausea 121 (50) 41 (17)* 23 (10)
Vomiting 82 (34) 19 (8) 14 (6)
Dizziness 48 (20) 25 (10) 17 (7)
Headache 45 (19) 16 (7) 18 (8)
Diarrhoea 40 (17) 23 (10) 21 (9)
Anorexia 34 (14) 8 (3) 4 (2)
Abdominal pain 29 (12) 11 (5) 7 (3)
Fatigue 23 (10) 5 (2) 6 (3)
Malaise 23 (10) 3 (1) 5 (2)
*P<0.05 compared with placebo (pairwise comparison based on Fisher’s exact test).
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one third of patients treated with 6›12 mg/day of
rivastigmine showed more than a 10% improvement.
Tolerability and safety
Adverse events leading to the discontinuation of treat›
ment were seen in 27% of patients taking 6›12 mg/day
of rivastigmine. The majority of these occurred during
the dose titration phase, which used a forced dose
escalation procedure and introduced an artificial
element into the trial design. Outside a clinical trial it is
likely that the dose escalation phase would be more
individualised and tolerance would improve.
The most common adverse events were related to
effects on acetylcholinesterase and were gastro›
intestinal. Most were mild and short lived and were
observed after increases in doses. There was no
evidence that rivastigmine compromised cardiovas›
cular function in these elderly patients, many of whom
had concomitant cardiovascular disease. The overall
incidence of serious adverse events was similar in all
three groups. Despite the age of the patients, the high
incidence of coexisting illnesses, and the use of
concomitant drug treatment, rivastigmine produced
no clinically relevant changes in laboratory tests,
electrocardiograms, on physical examination, or in
vital signs except for a small, statistically significant
decrease in mean body weight at higher doses.
This study provides clear evidence that rivastigmine
is effective in the treatment of patients with probable
Alzheimer’s disease and produces clinical benefits in a
significant percentage of patients on the three domains
measured. Improvements were still evident at the end of
the 6 month study, although further data are required to
determine the persistence of the results. Adverse events
were generally mild or moderate and occurred early in
treatment. The positive outcome of this study occurred
despite the variability in clinical practice between coun›
tries and the difficulties presented by differences in
language and culture. The results are qualitatively
similar to those of a study of similar design carried out in
the United States9 and add further evidence that
rivastigmine offers clinically meaningful benefits to
patients with Alzheimer’s disease.
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Key messages
x In a 6 month trial rivastigmine was effective in treating the core
cognitive and functional symptoms of patients with mild to
moderate Alzheimer’s disease
x Rivastigmine at doses of 6›12 mg/day produces clinically relevant
and statistically significant improvements in cognitive and global
assessments, and in activities of daily living
x The effects of rivastigmine are dose dependent
x Rivastigmine was well tolerated in this population of elderly patients
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Commentary: Another piece of the Alzheimer’s jigsaw
Tony Bayer
Rösler et al have published the results of the first large
trial of an acetylcholinesterase inhibitor used in a
mainly European population of patients with
Alzheimer’s disease. It provides further evidence of
modest cognitive and global benefits of acetyl›
cholinesterase inhibitor treatment and also shows
statistically significant functional benefits, with a
greater proportion of patients on higher dose rivastig›
mine (6›12 mg/day) compared with placebo improv›
ing their total score on the progressive deterioration
scale. This scale is completed by carers and was specifi›
cally developed for use with patients with Alzheimer’s
disease. It has been shown to be a valid and reliable
measure of drug effects in clinical trials. However, the
presentation—a visual analogue scale—can be prob›
lematic, and it is not suitable for use in everyday clini›
cal practice. The absence of measures of neuropsychi›
atric outcome and the burden on carers is unfortunate,
but in the past the choice of outcomes in clinical drug
trials in dementia was governed by requirements of
regulatory authorities rather than aims of measuring
the real impact of the illness on the lives of patients and
their families. The need for clinically relevant outcome
measures should now be better appreciated.
The authors emphasise that their patient popula›
tion was not highly selected. Nevertheless, all had been
carefully diagnosed at specialist centres using stand›
ardised clinical criteria, had symptoms of mild to mod›
erate severity, and only those with an available
caregiver and who were not taking other central nerv›
ous system drug treatment were included. Such
patients are not typical of those presenting to old age
psychiatrists and geriatricians.
One third of the patients on the higher dose of
rivastigmine discontinued treatment, presumably
despite close monitoring; the authors attribute this in
part to inappropriate forced dose escalation. How the
trial results might translate to everyday clinical practice
is therefore uncertain.
Response to treatment seemed to be variable, with
substantial improvement in a few patients and no obvi›
ous benefit in many. Averaging the change in test
scores, especially with selective presentation of
observed cases or an intention to treat analysis, can
easily mislead. Interpretation of the data would have
been helped by presenting the “number needed to
treat” to obtain clinically meaningful improvements in
outcomes. Rösler et al’s paper also tells us nothing
about the long term impact of acetylcholinesterase
inhibitor treatment on the considerable human and
economic costs of Alzheimer’s disease.
There are many pieces of the Alzheimer’s jigsaw
that are still missing. Future research efforts need to
focus on identifying predictors and better measures of
response, timing of treatment and optimum dose regi›
mens, longer term follow up, and establishing how and
when the use of acetylcholinesterase inhibitor drugs
should be stopped.
Competing interests: TB has received research grants and
fees for speaking from Novartis, Eisai, and Bayer.
Science commentary: Rational drug design for Alzheimer’s disease
The loss of cholinergic neurotransmitter activity was
first identified in the 1970s at necropsy in brains
removed from people with Alzheimer’s disease, and it
has since been confirmed in living patients by positron
emission tomography (figure). These observations
have led to the development of a number of acetylcho›
linesterase inhibitor drugs, which have been rationally
designed to boost the apparent chemical deficiency in
Alzheimer’s disease (MR Farlow et al, Neurology
1998;51(suppl 1):36›44S).
Acetylcholinesterase inhibitors have been designed
to stop the breakdown of acetylcholine in the brain.
Unfortunately, these drugs are non›selective and thus
the action of the enzyme is blocked in other parts of
the body, causing an undesirable build up of the
neurotransmitter at other sites. The gut is one of the
more common sites where this happens, and this can
lead to side effects such as increased motility and nau›
sea. Most of the drugs in this family are reversible—that
is, the action of the enzyme is only blocked while the
drug is being taken.
The chief pathways of acetylcholine that are
affected in Alzheimer’s disease seem to be in the series
of nuclei that project from the forebrain nucleus up to
the cerebral cortex and, more specifically, into the
hippocampus, which is known to be involved with the
function of memory. The aim is, therefore, to boost
acetylcholine concentrations in the hippocampus.
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Coloured positron emission tomography scans (horizontal sections)
of the brain of a normal patient (left) and a patient with Alzheimer’s
disease (right). Red and yellow areas show high brain activity; blue
and black areas show low activity. The scan from the patient with
Alzheimer’s disease shows that both function and blood flow in both
sides of the brain are reduced. Acetylcholinesterase inhibitor drugs
may boost the apparent chemical deficiency in Alzheimer’s disease.
The aim is to increase concentrations in the hippocampus, which is
involved in memory
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To date, most trials of the effectiveness of
acetylcholinesterase inhibitors in dementia have
followed patients for a minimum of six months. But no
one yet knows how quickly an alteration in acetylcho›
line concentrations might result in a measurable resto›
ration of memory. And, to achieve optimal benefits, it
may also prove necessary to offer a period of “retrain›
ing” to reorient the brain, in addition to improving the
neurotransmitter concentrations.
It remains to be seen how well these drugs actually
work in Alzheimer’s disease. In future it may be shown
that other types of dementia with less complex patho›
logical processes may be more responsive. One exam›
ple is the dementia associated with Lewy bodies in
which the pathological process does not also include
the presence of amyloid or tangles to the same extent
as in Alzheimer’s disease.
Abi Berger Science editor, BMJ
Patients’ and doctors’ attitudes to amount of information
given after unintended injury during treatment:
cross sectional, questionnaire survey
Melanie Hingorani, Tina Wong, Gilli Vafidis
Unintended injuries (adverse events) caused during
treatment are much more common than previously
believed.1 Recent legal and disciplinary cases have
shown that, although patients are increasingly dissatis›
fied with a perceived lack of openness in the medical
profession, doctors are not legally obliged to provide an
explanation after an adverse event.2 Because of this, the
General Medical Council has revised its guidance on
good medical practice, stating that after an adverse event
a full and honest explanation and an apology should be
provided routinely.3 We surveyed patients’ and doctors’
attitudes to the provision of information to patients after
a hypothetical adverse event in cataract surgery.
Subjects, methods, and results
A specifically designed questionnaire (box) was used to
survey all patients attending a consultant ophthal›
mologist’s clinic during five weeks in 1998; 246 of 302
(81%) patients agreed to participate. All 48 ophthal›
mologists attending a regional meeting also partici›
pated. The questionnaire asked about the post›
operative information that should be given routinely in
a hypothetical situation in which a common intra›
operative complication (posterior capsular rupture)
occurred in cataract surgery, with an estimated 10%
risk of an adverse effect on vision.
The attitudes of the patients differed substantially
from those of the ophthalmologists: 226 (92%) patients,
compared with only 29 (60%) ophthalmologists,
believed that a patient should always be told if a compli›
cation has occurred (÷2 = 34.5, 1 df, P < 0.001; odds ratio
7.4 (95% confidence interval 3.7 to 14.3)). The ophthal›
mologists who did not believe that patients should
always be told replied that either the patient should
never be told or that it depended on the circumstances.
Two hundred (81%) patients, but only 16 (33%) ophthal›
mologists, believed that a patient should not only be
informed of a complication but also be given detailed
information on possible adverse outcomes (÷2 = 47.1,
1 df, P < 0.001; 8.7 (4.7 to 15.9)).
Comment
Our survey shows that after an adverse event patients
expect more detailed information than doctors believe
should be given. Doctors’ reluctance to provide
detailed information to patients after adverse events is
often an attempt to protect the patient from potentially
detrimental anxiety. However, doctors may also avoid
telling patients because it is a time consuming, difficult,
and unpleasant task and because they fear losing a
patient’s trust, being blamed, and perhaps sued. In
addition, it has been suggested that the current medical
culture, in which error is often automatically equated
with professional incompetence or inadequacy, makes
admission to either patients or colleagues difficult.4
Many studies show, however, that failure to provide
information, an explanation, and an apology increases
the risk of litigation and erodes the patient›doctor rela›
tionship.5 After an adverse event, patients want
disclosure of the event, admission of responsibility, an
explanation, an apology, and prevention of future simi›
lar errors; in some cases, they also want the offender to
be punished and to obtain financial compensation.5
The practice of medicine can never be free of
errors,4 and changes are required in the attitudes of
both patients and the medical profession, with realistic
expectations of the limitations of doctors and medicine
and greater, blame free openness. In the light of the
new regulations from the General Medical Council,
failure to acknowledge an adverse event arising during
treatment may now have serious professional conse›
quences for a practitioner.
We thank Mr Jeremy Joseph for his advice.
Questionnaire
Please read the following story (which is typical but fictional):
Mrs Brown has an operation for cataract. During surgery, there is a complication.
The lens capsule breaks and the surgeon has to make a bigger cut than planned, use
stitches and put in a different style of lens implant. There is approximately a 1 in 10
chance of her vision being affected by these changes.
The next day, she sees well and is pleased.
Should Mrs Brown be told about the surgical problem? Yes / No
If yes, do we discuss the possible consequences? Yes / Only if she asks / No
Please comment on your decision overleaf.
What is your age? 25 and under / 26›60 years / over 60 years
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